Acasti Pharma (ACST) Stock Forecast, Price & News

Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions

Is Acasti Pharma a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Acasti Pharma stock.
View analyst ratings for Acasti Pharma or view top-rated stocks.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,140,000 shares, a decrease of 14.9% from the April 30th total of 1,340,000 shares. Based on an average daily volume of 155,600 shares, the short-interest ratio is currently 7.3 days. Currently, 3.6% of the shares of the company are short sold.
View Acasti Pharma's Short Interest.

When is Acasti Pharma's next earnings date?

Acasti Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, June 28th 2022.
View our earnings forecast for Acasti Pharma.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) released its quarterly earnings data on Thursday, August, 13th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.08.
View Acasti Pharma's earnings history.

When did Acasti Pharma's stock split? How did Acasti Pharma's stock split work?

Acasti Pharma shares reverse split on Tuesday, August 31st 2021. The 1-8 reverse split was announced on Tuesday, August 31st 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 31st 2021. An investor that had 100 shares of Acasti Pharma stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for ACST?

1 equities research analysts have issued 1-year price objectives for Acasti Pharma's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Acasti Pharma's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 533.6% from the stock's current price.
View analysts' price targets for Acasti Pharma or view top-rated stocks among Wall Street analysts.

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the following people:

• Ms. Janelle D'Alvise, Pres, CEO, Corp. Sec. & Director (Age 66, Pay $428.04k)
• Dr. Pierre Lemieux M.D., Ph.D., Co-Founder, COO & Chief Scientific Officer (Age 57, Pay $276.38k)
• Mr. Brian D. Ford CPA, CA, Chief Financial Officer (Age 63, Pay $364.82k)
• Dr. Yves Lachance Ph.D., VP of Quality & Compliance
• Ms. Christine Pelletier, Sr. Director of HR
• Dr. George Kottayil, Chief Operating Officer of US
• Mr. Prashant Kohli, VP of Commercial Operations

Who are some of Acasti Pharma's key competitors?

Some companies that are related to Acasti Pharma include Humanigen (HGEN), Matinas BioPharma (MTNB), KemPharm (KMPH), Impel Pharmaceuticals (IMPL), Vaccitech (VACC), Inozyme Pharma (INZY), TFF Pharmaceuticals (TFFP), Allakos (ALLK), PDS Biotechnology (PDSB), Savara (SVRA), Xeris Biopharma (XERS), Avadel Pharmaceuticals (AVDL), AVEO Pharmaceuticals (AVEO), Clene (CLNN) and ContraFect (CFRX).
View all of ACST's competitors.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."

How do I buy shares of Acasti Pharma?

Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately $0.95.

How much money does Acasti Pharma make?

Acasti Pharma has a market capitalization of $41.94 million and generates $200 thousand in revenue each year. The biopharmaceutical company earns $-19.68 million in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does Acasti Pharma have?

Acasti Pharma employs 32 workers across the globe.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is www.acastipharma.com.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5. The biopharmaceutical company can be reached via phone at 45-0686-4555, via email at [email protected], or via fax at 45-0687-2272.